Clinical Trials Browser

Adenocarcinoma of Lung, Burkitt Lymphoma, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Clinical Trials

SAFIR02_Lung

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Vandetanib in Advanced NSCLC With RET Rearrangement

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

ZELIG

Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

ZODIAC

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

ZD6474 Phase IIa Dose Finding Multicentre Study

ZD6474(Vandetanib) + Alimta Combo Study

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

ZD6474 in Treating Patients With Small Cell Lung Cancer

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma